Literature DB >> 30796709

Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter.

Sujata Sridharan1, Joel Raffel2, Ashwini Nandoskar2, Chris Record2, David J Brooks2,3,4, David Owen2, David Sharp2, Paolo A Muraro2, Roger Gunn5, Richard Nicholas2.   

Abstract

PURPOSE: Measurements of non-displaceable binding (VND) of positron emission tomography (PET) ligands are not often made in vivo in humans because they require ligands to displace binding to target receptors and there are few readily available, safe ones to use. A technique to measure VND for ligands for the 18-kDa translocator protein (TSPO) has recently been developed which compares the total volume of distribution (VT) before and after administration of the TSPO ligand XBD173. Here, we used XBD173 with an occupancy plot to quantify VND for two TSPO radiotracers, [18F]GE-180 and [11C]PBR28, in cohorts of people with multiple sclerosis (MS). Additionally, we compared plots of subjects carrying high (HAB) or mixed binding (MAB) affinity polymorphisms of TSPO to estimate VND without receptor blockade. PROCEDURES: Twelve people with MS underwent baseline MRI and 90-min dynamic [18F]GE-180 PET or [11C]PBR28 PET (n = 6; three HAB, three MAB each). Arterial blood sampling was used to generate plasma input functions for the two-tissue compartment model. VND was calculated using two independent methods: the occupancy plot (by modelling the differences in signal post XBD173) and the polymorphism plot (by modelling the differences in signal across presence and absence of rs6971 genotypes).
RESULTS: Whole brain VT (mean ± standard deviation) was 0.29 ± 0.17 ml/cm3 for [18F]GE-180 and 5.01 ± 1.88 ml/cm3 for [11C]PBR28. Using the occupancy and polymorphism plots respectively, VND for [18F]GE-180 was 0.11 ml/cm3 (95 % CI = 0.02, 0.16) and 0.20 ml/cm3 (0.16, 0.34), accounting for, on average, 55 % of VT in the whole brain. For [11C]PBR28, these values were 3.81 ml/cm3 (3.02, 4.21) and 3.49 ml/cm3 (1.38, 4.27), accounting for 67 % of average whole brain VT.
CONCLUSIONS: Although VT for [18F]GE-180 is low, indicating low brain penetration, half the signal shown by MS subjects reflected specific TSPO binding. VT for [11C]PBR28 was higher and two thirds of the binding was non-specific. No brain ROIs were devoid of specific signal, further confirming that true reference tissue approaches are potentially problematic for estimating TSPO levels.

Entities:  

Keywords:  Multiple sclerosis; Occupancy plot; PET; Polymorphism plot; XBD173; [11C]PBR28; [18F]GE-180

Mesh:

Substances:

Year:  2019        PMID: 30796709     DOI: 10.1007/s11307-019-01323-8

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  34 in total

1.  Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited.

Authors:  Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-09       Impact factor: 6.200

2.  [¹⁸F]GE-180: a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO).

Authors:  Harry Wadsworth; Paul A Jones; Wai-Fung Chau; Clare Durrant; Naghmeh Fouladi; Joanna Passmore; Dennis O'Shea; Duncan Wynn; Veronique Morisson-Iveson; Amanda Ewan; Mikkel Thaning; Dimitrios Mantzilas; Ingvil Gausemel; Imtiaz Khan; Andrew Black; Michelle Avory; William Trigg
Journal:  Bioorg Med Chem Lett       Date:  2011-12-27       Impact factor: 2.823

3.  Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation.

Authors:  David R Owen; Owain W Howell; Sac-Pham Tang; Lisa A Wells; Idriss Bennacef; Mats Bergstrom; Roger N Gunn; Eugenii A Rabiner; Martin R Wilkins; Richard Reynolds; Paul M Matthews; Christine A Parker
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-28       Impact factor: 6.200

4.  Kinetic modelling of [11C]PBR28 for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis.

Authors:  Mattia Veronese; Tiago Reis Marques; Peter S Bloomfield; Gaia Rizzo; Nisha Singh; Deborah Jones; Erjon Agushi; Dominic Mosses; Alessandra Bertoldo; Oliver Howes; Federico Roncaroli; Federico E Turkheimer
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-05       Impact factor: 6.200

5.  Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907.

Authors:  H Watabe; M A Channing; M G Der; H R Adams; E Jagoda; P Herscovitch; W C Eckelman; R E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2000-06       Impact factor: 6.200

6.  Head-to-Head Comparison of 11C-PBR28 and 18F-GE180 for Quantification of the Translocator Protein in the Human Brain.

Authors:  Paolo Zanotti-Fregonara; Belen Pascual; Gaia Rizzo; Meixiang Yu; Neha Pal; David Beers; Randall Carter; Stanley H Appel; Nazem Atassi; Joseph C Masdeu
Journal:  J Nucl Med       Date:  2018-01-18       Impact factor: 10.057

7.  Identification of brain regions predicting epileptogenesis by serial [18F]GE-180 positron emission tomography imaging of neuroinflammation in a rat model of temporal lobe epilepsy.

Authors:  Vera Russmann; Matthias Brendel; Erik Mille; Angela Helm-Vicidomini; Roswitha Beck; Lisa Günther; Simon Lindner; Axel Rominger; Michael Keck; Josephine D Salvamoser; Nathalie L Albert; Peter Bartenstein; Heidrun Potschka
Journal:  Neuroimage Clin       Date:  2017-04-05       Impact factor: 4.881

8.  Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats.

Authors:  Sujata Sridharan; Francois-Xavier Lepelletier; William Trigg; Samuel Banister; Tristan Reekie; Michael Kassiou; Alexander Gerhard; Rainer Hinz; Hervé Boutin
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

9.  Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study.

Authors:  David R Owen; Qi Guo; Nicola J Kalk; Alessandro Colasanti; Dimitra Kalogiannopoulou; Rahul Dimber; Yvonne L Lewis; Vincenzo Libri; Julien Barletta; Joaquim Ramada-Magalhaes; Aruloly Kamalakaran; David J Nutt; Jan Passchier; Paul M Matthews; Roger N Gunn; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2014-03-19       Impact factor: 6.200

10.  Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain.

Authors:  Claire Feeney; Gregory Scott; Joel Raffel; S Roberts; Christopher Coello; Amy Jolly; Graham Searle; A P Goldstone; David J Brooks; Richard S Nicholas; William Trigg; Roger N Gunn; David J Sharp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-28       Impact factor: 9.236

View more
  20 in total

1.  Concentration, distribution, and influence of aging on the 18 kDa translocator protein in human brain: Implications for brain imaging studies.

Authors:  Junchao Tong; Belinda Williams; Pablo M Rusjan; Romina Mizrahi; Jean-Jacques Lacapère; Tina McCluskey; Yoshiaki Furukawa; Mark Guttman; Lee-Cyn Ang; Isabelle Boileau; Jeffrey H Meyer; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-20       Impact factor: 6.200

2.  In response to: The validity of 18F-GE180 as a TSPO imaging agent.

Authors:  Nathalie L Albert; Marcus Unterrainer; Matthias Brendel; Lena Kaiser; Markus Zweckstetter; Paul Cumming; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-02       Impact factor: 9.236

3.  TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study.

Authors:  M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-05       Impact factor: 9.236

4.  Letter to the Editor re: Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter.

Authors:  Paolo Zanotti-Fregonara; Mattia Veronese; Gaia Rizzo; Belen Pascual; Joseph C Masdeu; Federico E Turkheimer
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

5.  Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas.

Authors:  Lena Kaiser; Adrien Holzgreve; Stefanie Quach; Michael Ingrisch; Marcus Unterrainer; Franziska J Dekorsy; Simon Lindner; Viktoria Ruf; Julia Brosch-Lenz; Astrid Delker; Guido Böning; Bogdana Suchorska; Maximilian Niyazi; Christian H Wetzel; Markus J Riemenschneider; Sophia Stöcklein; Matthias Brendel; Rainer Rupprecht; Niklas Thon; Louisa von Baumgarten; Jörg-Christian Tonn; Peter Bartenstein; Sibylle Ziegler; Nathalie L Albert
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 6.  Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.

Authors:  Aline M Thomas; Frederik Barkhof; Jeff W M Bulte
Journal:  Radiology       Date:  2022-04-26       Impact factor: 29.146

7.  In Response to Letter from Fregonara et al. 2019.

Authors:  Richard Nicholas; David Brooks; David Owen
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

Review 8.  PET imaging of neuroinflammation in neurological disorders.

Authors:  William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis
Journal:  Lancet Neurol       Date:  2020-11       Impact factor: 44.182

9.  Perspective: Solving the Heterogeneity Conundrum of TSPO PET Imaging in Psychosis.

Authors:  Livia De Picker; Manuel Morrens
Journal:  Front Psychiatry       Date:  2020-05-01       Impact factor: 4.157

10.  Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders.

Authors:  Franziska J Vettermann; Stefanie Harris; Julia Schmitt; Marcus Unterrainer; Simon Lindner; Boris-Stephan Rauchmann; Carla Palleis; Endy Weidinger; Leonie Beyer; Florian Eckenweber; Sebastian Schuster; Gloria Biechele; Christian Ferschmann; Vladimir M Milenkovic; Christian H Wetzel; Rainer Rupprecht; Daniel Janowitz; Katharina Buerger; Robert Perneczky; Günter U Höglinger; Johannes Levin; Christian Haass; Joerg C Tonn; Maximilian Niyazi; Peter Bartenstein; Nathalie L Albert; Matthias Brendel
Journal:  Life (Basel)       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.